Position: Home > News

Focusing on advanced tumors, Bragg's treatment shows its true achievements

Author:admin      Time:2022-06-10     Number :111
"I didn't have much hope at first, but I didn't expect that after this therapy, I feel much better! Your medical level is still high!!!" A long-lost smile appeared on Lao Zhao's face.

Recently, Lu Jun, director of the Radiation Therapy Center of Xi'an International Medical Center Hospital, led a team using the Prague treatment plan to determine a significant curative effect for Lao Zhao, a 58-year-old patient with multiple metastatic tumors after surgery for Her-2 positive gastric cancer.

Lao Zhao, who lives in Xianyang, developed stomach cramps and acid reflux at the end of 2020. Later, gastric cancer was detected in another hospital, and distal gastrectomy was performed. The postoperative clinical stage was pT3N3aM0. Adjuvant chemotherapy with SOX regimen was used for 6 cycles. Originally, his condition was controlled after surgery and chemotherapy, but he did not expect to find liver metastases during the re-examination in November 2021. Later, Lao Zhao continued to use targeted therapy combined with chemotherapy. After multiple treatments, he still could not resist the speed of tumor metastasis. He saw that his body was gradually losing weight and turning yellow, and the symptoms of upper abdominal pain gradually increased. With the last glimmer of hope, Lao Zhao asked around for medical treatment, and finally came to the Radiation Therapy Center of Xi'an International Medical Center Hospital.



After admission, the army director instructed to complete the patient's baseline level examination to evaluate the condition. Surprisingly, the patient developed multiple lymph node metastases in the left supraclavicular, mediastinum, right cardiophrenic angle area and bilateral hilum, multiple metastases in both lungs, and liver. Multiple metastases and obstructive jaundice. Faced with the rapid progress of the disease, how to further control the disease and relieve the patient's symptoms has become a difficult problem faced by the army director team.

For patients with multiple metastases after tumor surgery and failure of multiple lines of therapy, survival is obvious. Faced with this situation, the director of the army led the team to find a new way to quickly formulate a treatment plan, using the anti-Her-2 antibody-conjugated drug Vidicitumumab combined with the Bragg regimen for treatment.

After the patient completed 1 cycle of treatment, the symptoms of upper abdominal pain basically disappeared, the symptoms of obstructive jaundice were relieved, the tumor index decreased (Figure 1), the multiple lung metastases disappeared and shrunk (Figure 2), and the bilateral hilar lymph nodes shrunk (Figure 3). , multiple liver metastases shrunk (Figure 4).



According to the director of the army, Her-2 gene plays an important role in the occurrence and development of various malignant tumors, and the treatment of Her-2 positive patients is still a difficult problem in tumor treatment. In the face of this patient, in the case of failure of targeted therapy and poor control of the disease, in order to improve the efficiency, the anti-Her-2 antibody conjugated drug Veldicitumab was combined with Bragg therapy, and received a significant effect.

Bragg therapy is an innovative tumor immunotherapy that combines PD-1 inhibitors, radiotherapy (Radiotherapy) and granulocyte-macrophage stimulating factor (GM-CSF) to produce an ideal in situ vaccine effect and save advanced disease. the lives of cancer patients. The first letter combination of the three elements in this technology is "PRaG", and because the "Bragg peak" is of great significance in radiotherapy, the treatment technology is named "Bragg treatment".

In layman's terms, Bragg treatment is to form a "tumor vaccine effect" through the ionizing radiation of radiotherapy, and use PD-1 inhibitor and GM-CSF as adjuvants to enhance the immune response of the "tumor vaccine", reflecting the "harmony between human and tumor". concept, and then achieve effective control of advanced tumors.

The innovation of this treatment concept breaks the indication that stereotactic radiotherapy (SBRT) is only for the treatment of early tumor lesions. For patients with advanced tumors, reasonable tumor lesions are selected for radiotherapy, combined with PD-1 inhibitors and GM-CSF, The anti-tumor effect of 1 1 1 > 3 was exerted.

From "talking about the discoloration of cancer" to "coexisting with cancer", how to prevent the recurrence and metastasis of tumors and improve the quality of life of patients has always been a topic explored by the radiation therapy center. Under the leadership of the director of the army, the medical staff in the department adhere to the concept of "cherish every service and do it well", and make every effort to provide high-quality medical services for every tumor patient.